Wang, M. L., Jurczak, W., Zinzani, P. L., Eyre, T. A., Cheah, C. Y., Ujjani, C. S., Koh, Y., Izutsu, K., Gerson, J. N., Flinn, I., Tessoulin, B., Alencar, A. J., Ma, S., Lewis, D., Lech-Maranda, E., Rhodes, J., Patel, K., Maddocks, K., Lamanna, N., … Shah, N. N. (2023). Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. Journal of Clinical Oncology, 41(24), 3988–3997. https://doi.org/10.1200/jco.23.00562

Vilarrasa-Blasi, R., Verdaguer-Dot, N., Belver, L., Soler-Vila, P., Beekman, R., Chapaprieta, V., Kulis, M., Queirós, A. C., Parra, M., Calasanz, M. J., Agirre, X., Prosper, F., Beà, S., Colomer, D., Marti-Renom, M. A., Ferrando, A., Campo, E., & Martin-Subero, J. I. (2021). Insights into the mechanisms underlying aberrant SOX11 oncogene expression in mantle cell lymphoma. Leukemia, 36(2), 583–587. https://doi.org/10.1038/s41375-021-01389-w